Keith Akama serves as the Principal Scientist at Lycia Therapeutics, where he leads the Engineering and Expression team within the Biologics Department. His focus is on pioneering innovative protein-based technologies aimed at addressing complex human diseases through the development of first-in-class therapeutics. With a specialization...
Keith Akama serves as the Principal Scientist at Lycia Therapeutics, where he leads the Engineering and Expression team within the Biologics Department. His focus is on pioneering innovative protein-based technologies aimed at addressing complex human diseases through the development of first-in-class therapeutics. With a specialization in bi- and multi-specific antibodies, Keith is at the forefront of designing recombinant biologics that not only meet efficacy and safety standards but also ensure manufacturability.
His expertise in molecular biology is complemented by a robust skill set in protein expression, enabling him to design and generate high-quality recombinant proteins and cell lines for therapeutic discovery. Keith's direct involvement in two patent applications related to bispecific antibodies underscores his commitment to advancing the field and contributing to the development of novel therapeutic modalities.
At Lycia, his team is dedicated to engineering therapeutics that degrade extracellular proteins, a strategy that holds promise for treating diseases that have been historically challenging to manage. Keith’s proficiency in in vitro techniques, project management, and molecular neuroscience, combined with his understanding of mechanisms of action and cell signaling pathways, positions him as a key player in the development of transformative therapies. His work not only advances scientific knowledge but also has the potential to significantly impact patient care by addressing unmet medical needs.
